



AMENDMENTS

In the specification

Page 14, line 13, please replace " _____ " with --60/031,306--.

Page 78, line 8, please replace " _____ " with --60/031,306--.

In the claims

20. (Twice amended) A polypeptide having immunological activity of anti-idiotypic antibody 11D10, wherein the polypeptide comprises [at least one complementarity determining region (CDR) from the light or heavy chain variable region of 11D10] an immunoglobulin variable region containing three light chain complementary determining regions (CDRs) of antibody 11D10, or an immunoglobulin variable region containing three light chain CDRs of antibody 11D10, wherein the light chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC No. HB 12020 or progeny thereof, and wherein the heavy chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC No. HB 12020 or progeny thereof, and wherein the immunological activity of the polypeptide is an ability to stimulate a specific immune response against human milk fat globule (HMFG).

Claim 21 (Amended), first line, please replace "a" with --the--.

Claim 22 (Amended), first line, please replace "a" with --the--.

26. (Amended) The polypeptide of claim 20, wherein the polypeptide contains a [region that is] sequence of at least 2 contiguous amino acids [homologous] which are identical in forward or reverse orientation to 2 contiguous amino acids of a tandem repeat sequence in human mucin from human milk fat globule.

RECEIVED

OCT 06 1999

TECH CENTER 1600/2900

Claim 29 (Amended), after "is", please delete "GM-CSF" and substitute --granulocyte

Σ 3 macrophage colony stimulating factor--.

Claim 30 (Amended), after "is" please delete "IL-2" and substitute --interleukin 2--.

Σ 4
31. (Amended) The fusion polypeptide of claim 27, [comprising at least 10 contiguous amino acids of light chain variable region depicted within SEQ ID NO:2 and at least 10 contiguous amino acids of heavy chain variable region depicted within SEQ ID NO:4] which comprises three CDRs from the light chain variable region of 11D10 and 3 CDRs from the heavy chain variable region of 11D10, wherein the CDRs from 11D10 are contained in an antibody produced by a hybridoma cell line designated ATCC NO. HB12020 or progeny thereof.

mb
#3
32. (Amended) The fusion polypeptide of claim 31, wherein the contiguous amino acids of SEQ ID NO:2 and the contiguous amino acids of SEQ ID NO:4 are joined by a linker polypeptide of about 5 to 20 amino acids.

Claim 33 (Amended), first line, please replace "a" with --the--; second line, please replace "a" with --the--; second line, please delete "monoclonal".

Σ 5
35. (Amended) A humanized antibody comprising [the polypeptide of claim 20] three CDRs from the light chain variable region of 11D10 and three-CDRs from the heavy chain variable region of 11D10, wherein the humanized antibody is able to stimulate a specific immune response against human milk fat globule (HMFG), wherein the light chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC No. HB 12020 or progeny thereof, and wherein the heavy chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line

Σ5 designated ATCC No. HB 12020 or progeny thereof, and wherein the immunological activity of the polypeptide is an ability to stimulate a specific immune response against human milk fat globule (HMFG).

Σ6
39. (Twice amended) A composition comprising [the] a pharmaceutically acceptable excipient and a polypeptide [of claim 20 and a pharmaceutically acceptable excipient] having immunological activity of anti-idiotypic antibody 11D10, wherein the polypeptide comprises at least one complementarity determining region (CDR) from the light or heavy chain variable region of 11D10, wherein the light chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC NO. HB 12020 or progeny thereof, and wherein the heavy chain variable region amino acid sequence is contained in an antibody produced by a hybridoma cell line designated ATCC NO. HB 12020 or progeny thereof, and wherein the immunological activity of the polypeptide is an ability to stimulate a specific immune response against human milk fat globule (HMFG).

Claim 43 (Twice amended), please delete "37" and substitute --40--.

Please add the following new claims.

Σ7
62. (New) The composition of claim 39, wherein the specific immune response comprises production of HMFG-specific antibody.

63. (New) The composition of claim 39, wherein the specific immune response comprises production of HMFG-specific T cells.

64. (New) The humanized antibody of claim 35, wherein the specific immune response comprises production of HMFG-specific antibody.